Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 4070

Drug Profile

ASP 4070

Alternative Names: ASP JRCv2.0; ASP-4070; CryJ2 -DNA-LAMP; CryJ2 DNA LAMP plasmid vaccine; CryJ2-DNA-lysosomal associated membrane protein plasmid; Japanese red cedar LAMP vaccine; Japanese red cedar pollen allergy immunotherapy - Immunomic; JRC LAMP vaccine; JRC LAMP vax vaccine; JRC-LAMP-vax; JRC2-LAMP-vax; Sugi allergy vaccine

Latest Information Update: 27 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma; Immunomic Therapeutics
  • Class DNA vaccines; Japanese cedar pollen allergy immunotherapies; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinitis; Allergic rhinoconjunctivitis; Tree pollen hypersensitivity

Most Recent Events

  • 27 Sep 2021 Discontinued - Phase-II for Tree pollen hypersensitivity in Japan (Intradermal)
  • 27 Oct 2018 Astellas Pharma completes a phase II trial in Tree-pollen hypersensitivity in Japan (NCT03101267)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Tree pollen hypersensitivity in Japan (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top